Skip to main
IMCR

Immunocore Holdings (IMCR) Stock Forecast & Price Target

Immunocore Holdings (IMCR) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 17%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Immunocore Holdings is poised for success in the oncology, infectious disease, and autoimmune markets with a deep pipeline and commercially successful KIMMTRAK product. The company's unique ImmTAX platform, which includes Brenetafusp and other candidates, has shown promise in 5-year survival data, with a 16% rate compared to just 8% in the control arm with investigator's choice. Additionally, with the potential approval of KIMMTRAK for cutaneous melanoma, there is significant upside for the stock in the future.

Bears say

Immunocore Holdings is facing several challenges ahead despite its current success, including potential slow growth in 2026 due to saturation in major markets and increased competition in its pipeline, as well as no guarantee of success in its ongoing clinical programs. Additionally, the company's decision not to expand KIMMTRAK to other HLA types may limit its potential market size and revenues. While Immunocore's current financials look promising, it is important to closely monitor its future developments and address these concerns to formulate a more positive outlook on the company's stock.

Immunocore Holdings (IMCR) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 17% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunocore Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunocore Holdings (IMCR) Forecast

Analysts have given Immunocore Holdings (IMCR) a Buy based on their latest research and market trends.

According to 6 analysts, Immunocore Holdings (IMCR) has a Buy consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $59.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $59.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunocore Holdings (IMCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.